<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02666846</url>
  </required_header>
  <id_info>
    <org_study_id>FM52</org_study_id>
    <nct_id>NCT02666846</nct_id>
  </id_info>
  <brief_title>Assess the Efficacy and Safety in Volunteers of DCF100, TIB200 and SPR300 vs. Placebo and Control(s) in a UV Pain Model</brief_title>
  <official_title>A Randomised, Double Blind, Cross Over Clinical Study in Healthy Human Volunteers to Assess the Efficacy and Safety of Three Different Topical Analgesics (DCF100, TIB200 And SPR300) Versus in a Model of UV-Induced Inflammatory Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Futura Medical Developments Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Parexel</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Futura Medical Developments Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomised, double blind, cross over clinical study in healthy human volunteers&#xD;
      (including pharmacokinetic [PK] sampling and laser Doppler assessment of local blood flow in&#xD;
      a subset of up to 6 subjects per cohort of 20) to assess the efficacy and safety of three&#xD;
      different topical analgesics (DCF100, TIB200 and SPR300) versus placebo and active control(s)&#xD;
      in a model of UV-induced inflammatory pain.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomised, double blind, cross over clinical study in healthy human volunteers,&#xD;
      including pharmacokinetic (PK) sampling and laser Doppler assessment of local blood flow in a&#xD;
      subset of up to 6 subjects per cohort, to assess the efficacy and safety of three different&#xD;
      topical analgesics (DCF100, TIB200 and SPR300) versus placebo and active control(s) in a&#xD;
      model of UV-induced inflammatory pain. The study will consist of 3 cohorts of subjects (n=20&#xD;
      subjects per cohort). Subjects of each cohort will receive test and reference products (no&#xD;
      reference product for Cohort 3) of one investigational medicinal product (IMP) and a placebo.&#xD;
&#xD;
      Test Products:&#xD;
&#xD;
      Cohort 1: Ibuprofen, TIB200 gel (10%, w/w) Cohort 2: Diclofenac, DCF100 gel (2% or 4%, w/w)&#xD;
      Cohort 3: Methyl-salicylate and Menthol, SPR300 gel (15%:7%, w/w; ratio of Methylsalicylate&#xD;
      to Menthol)&#xD;
&#xD;
      Reference Products:&#xD;
&#xD;
      Cohort 1: Ibuprofen, Nurofen Max Strength gel (10%, w/w), Ibuprofen, Nurofen, oral tablet&#xD;
      (400 mg) Cohort 2: Voltaren Emulgel (2%), Voltarol oral tablet (50 mg)&#xD;
&#xD;
      Placebo:&#xD;
&#xD;
      All Cohorts:Test product matching vehicle gel.&#xD;
&#xD;
      Pharmacodynamic tests and PK blood draws will be performed at: pre-dose, 1, 2, 4, and 6 hours&#xD;
      post dose for all treatment cohorts and treatment days (PK blood sampling in up to 6 subjects&#xD;
      per cohort only).&#xD;
&#xD;
      Safety will be evaluated by the incidence of local and systemic treatment-emergent adverse&#xD;
      events (TEAEs) reported after each treatment. Safety assessments will also include vital&#xD;
      signs, 12-Lead Electrocardiograms (ECGs), laboratory tests and a physical examination at&#xD;
      Screening and the Follow-up visit.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Actual">May 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Heat Pain Tolerance Test (HPTT) Measured the Point at Which the Heat Became Painful - Degrees Centigrade -</measure>
    <time_frame>15 minutes before to 6 hours post administration</time_frame>
    <description>To assess the pharmacodynamic effect by Heat Pain Tolerance Test (HPTT) which measured the point at which the heat became painful (degrees centigrade) of three topical analgesics, DCF100, TIB200, and SPR300 versus topical placebo and active topical reference products in a model of UV-induced inflammatory pain.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Intensity of the UVB-induced Erythema (Determined by Assessment of Skin Blood Flow by Laser Doppler Imaging [Flux Units])</measure>
    <time_frame>15 minutes before to 6 hours post administration</time_frame>
    <description>Intensity of the Ultra Violet B radiation (UVB)-induced erythema (determined by assessment of skin blood flow by laser Doppler imaging [flux units], up to 8 subjects per cohort) - Change from baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Peak Plasma Concentration (Cmax)</measure>
    <time_frame>15 minutes before and 1, 2, 4 and 6 hours post administration</time_frame>
    <description>Maximum observed plasma concentration (Cmax), time corresponding to occurrence of Cmax (tmax) (up to 6 subjects per cohort only) laser Doppler imaging [flux units], up to 6 subjects per cohort)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration Versus Time Curve</measure>
    <time_frame>15 minutes before and 1, 2, 4 and 6 hours post administration</time_frame>
    <description>Area under the concentration vs. time curve from time zero to 6 hours (AUC0-6h) (up to 6 subjects per cohort only) laser Doppler imaging [flux units], up to 6 subjects per cohort)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Recorded Abnormal Clinical Assessments</measure>
    <time_frame>Estimated study duration for each subject will be approximately 6 weeks</time_frame>
    <description>Laboratory assessments - standard clinical trial assessments for clinical chemistry and haematology&#xD;
Listing of individual laboratory measurements by subjects and evaluation of each laboratory parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical Exams to Ensure Safety and Well Being of the Subjects</measure>
    <time_frame>Estimated study duration for each subject will be approximately 6 weeks</time_frame>
    <description>Physical examinations - including assessments of the application site. examination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events (AEs)</measure>
    <time_frame>Estimated study duration for each subject will be approximately 6 weeks</time_frame>
    <description>Local and systemic Adverse Events (AEs).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Determine Vital Signs and Electrocardiograms (ECGs) That Were Abnormal to Ensure Safety and Well Being of the Subjects</measure>
    <time_frame>Estimated study duration for each subject will be approximately 6 weeks</time_frame>
    <description>To determine Vital Signs and Electrocardiograms (ECGs) that were abnormal to ensure safety and well being of the subjects</description>
  </secondary_outcome>
  <number_of_arms>11</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Cohort 1: TIB200 gel 10%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All Cohort 1 participants: TIB200 gel (10%, w/w ibuprofen)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1: Nurofen gel 10%</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>All Cohort 1 participants: Nurofen Max Strength gel (10%, w/w ibuprofen)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1: Nurofen tablets</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>All Cohort 1 participants: Nurofen oral tablets (2 x 400 mg ibuprofen)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1: TIB200 Placebo gel</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>All Cohort 1 Participants: TIB200 matching placebo gel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: DCF100 gel 2%</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>All Cohort 2 Participants: DCF100 gel (2% w/w diclofenac)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: DCF100 gel 4%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All Cohort 2 Participants: DCF100 gel (4% w/w diclofenac)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: Voltaren gel 2%</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>All Cohort 2 Participants: Voltaren Emulgel (2% diclofenac)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: Voltarol oral tablet</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>All Cohort 2 Participants: Voltarol oral tablet (50 mg - diclofenac)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: DCF100 Placebo gel</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>All Cohort 2 Participants: DCF100 matching placebo gel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3: SPR300 gel (15%:7%)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>All Cohort 3 Participants: Methyl-salicylate / Menthol, SPR300 gel (15%:7%, w/w; ratio of Methylsalicylate / Menthol)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3: SPR300 Placebo gel</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>All Cohort 3 Participants: SPR300 matching placebo gel</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibuprofen</intervention_name>
    <arm_group_label>Cohort 1: Nurofen gel 10%</arm_group_label>
    <arm_group_label>Cohort 1: Nurofen tablets</arm_group_label>
    <arm_group_label>Cohort 1: TIB200 gel 10%</arm_group_label>
    <other_name>TIB200 gel 10%, Nurofen gel 10%, Nurofen tablets</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diclofenac</intervention_name>
    <arm_group_label>Cohort 2: DCF100 gel 2%</arm_group_label>
    <arm_group_label>Cohort 2: DCF100 gel 4%</arm_group_label>
    <arm_group_label>Cohort 2: Voltaren gel 2%</arm_group_label>
    <arm_group_label>Cohort 2: Voltarol oral tablet</arm_group_label>
    <other_name>DCF100 gel 2%, DCF100 gel 4%, Voltaren gel 2%, Voltaren oral tablet</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methyl-salicylate / Menthol</intervention_name>
    <arm_group_label>Cohort 3: SPR300 gel (15%:7%)</arm_group_label>
    <other_name>SPR300 gel (15%/7%)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Cohort 1: TIB200 Placebo gel</arm_group_label>
    <arm_group_label>Cohort 2: DCF100 Placebo gel</arm_group_label>
    <arm_group_label>Cohort 3: SPR300 Placebo gel</arm_group_label>
    <other_name>TIB200 placebo gel, DCF100 placebo gel and SPR300 placebo gel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Were able to provide written informed consent.&#xD;
&#xD;
          2. Male between 18 and 65 years old, inclusive, at the time of screening.&#xD;
&#xD;
          3. Good general health as ascertained by detailed medical history and physical&#xD;
             examination.&#xD;
&#xD;
          4. Body mass index (BMI) ≥18 and ≤29 kg/m2 (BMI = weight/height2), at the time of&#xD;
             screening.&#xD;
&#xD;
          5. No clinically relevant abnormalities in 12-lead ECG as per PI's judgement, e.g.,&#xD;
             absence of cardiac rhythm disorder, in particular bradycardia (&lt;40 beats per minute),&#xD;
             conduction abnormalities such as atrioventricular block, absence of active ischemia&#xD;
             (such as unstable angina pectoris) or recent myocardial infarction, no QTcF interval&#xD;
             &gt;450 milliseconds, no QRS complex ≥120 milliseconds, at Screening.&#xD;
&#xD;
          6. No clinically relevant abnormalities in results of laboratory tests as per PI's&#xD;
             judgement; in particular, no significant liver impairment defined as aspartate&#xD;
             aminotransferase (AST), alanine aminotransferase (ALT) 1.5x upper limit of normal&#xD;
             (ULN); no significant kidney impairment defined as serum creatinine 2x ULN; abnormal&#xD;
             thyroid function as defined by thyroid-stimulating hormone (TSH) and total thyroxin&#xD;
             (T4) (TSH within range 0.27 to 4.2 mIU/L, total T4 within range 59 to 154 nmol/L).&#xD;
&#xD;
          7. Had a skin type II or III (Fitz Patrick classification).&#xD;
&#xD;
          8. Non-smokers or ex-smokers for at least 6 months prior to the Screening Visit, as&#xD;
             confirmed by a urine cotinine test.&#xD;
&#xD;
          9. Subjects were able to communicate well with the PI/designee. -&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of hypersensitivity to the IMP or any of the excipients or to medicinal&#xD;
             products with similar chemical structures.&#xD;
&#xD;
          2. Presence of any clinically relevant acute or chronic disease which could interfere&#xD;
             with the subject safety during the study, expose the subject to undue risk, limit the&#xD;
             biological sampling (e.g., blood collection), interfere with the absorption of the IMP&#xD;
             (e.g., active dermatological conditions at the application sites, or ulcers, irritable&#xD;
             bowel syndrome) or interfere with the study objectives.&#xD;
&#xD;
          3. Skin type I, IV, V or VI (Fitzpatrick Classification).&#xD;
&#xD;
          4. History of chronic pain symptoms (&gt;6 months) or ongoing pain.&#xD;
&#xD;
          5. Any condition that required regular concomitant medication including herbal products,&#xD;
             or predicted need of any concomitant medication from Screening Visit until the end of&#xD;
             the study.&#xD;
&#xD;
          6. Intake of any medication including over the counter (OTC) medication (in particular&#xD;
             any pain killers), herbal and dietary supplements such as St John's Wort, vitamins and&#xD;
             minerals that could affect the outcome of the study, within 48 hours before the first&#xD;
             administration of the investigational product and for the duration of the study.&#xD;
&#xD;
          7. Use of photosensitising medication, such as phenothiazines, tetracyclines, quinolones,&#xD;
             sulphonamides, nalidixic acid, non-steroidal anti-inflammatories, furosemides,&#xD;
             hydrochlorothiazides, fibrate, phytotherapeutic drugs (herbal supplements),&#xD;
             phenothiazines, quinidines, psoralens and amiodarone within 4 weeks before the first&#xD;
             UVB irradiation and for the duration of the study.&#xD;
&#xD;
          8. Any skin disease, acute or chronic (e.g., psoriasis vulgaris, neurodermatitis) or auto&#xD;
             immune diseases associated with increased light sensitisation.&#xD;
&#xD;
          9. Any active dermatological conditions, local pigmentary disorders, body art (e.g.,&#xD;
             tattoos), or excessive hair growth at the lower back that might interfere with the&#xD;
             study assessments or absorption of the IMP.&#xD;
&#xD;
         10. History of skin cancer (i.e., melanoma, squamous cell carcinoma or basal cell&#xD;
             carcinoma).&#xD;
&#xD;
         11. History of conditions that increase risk for melanoma (e.g., dysplastic nevus [&gt;5&#xD;
             nevi], xeroderma pigmentosum, Fanconi anaemia, Bloom's syndrome, Werner syndrome,&#xD;
             Cockayne syndrome, trichothiodystrophy, or familial mole melanoma syndrome).&#xD;
&#xD;
         12. History of bleeding disorders, peptic ulceration or gastro intestinal bleeding, heart&#xD;
             burn, cardiovascular disease, myocardial infarction or stroke.&#xD;
&#xD;
         13. Inability to give reproducible HPPT ratings on naïve skin at screening, (defined as&#xD;
             HPTT test re-test difference ≥1.0 °C)&#xD;
&#xD;
         14. Heat pain perception threshold &lt;40°C or &gt;51°C on naïve skin at Screening.&#xD;
&#xD;
         15. Supine systolic blood pressure (SBP) &lt;90 mmHg or &gt;140 mmHg, or supine diastolic blood&#xD;
             pressure (DBP) &lt;50 mmHg or &gt;90 mmHg after 5 minutes supine, at the Screening Visit.&#xD;
&#xD;
         16. Positive test results for HBsAg, HCVAb or HIV-1 and/or -2 antibodies at Screening.&#xD;
&#xD;
         17. Excessive use of caffeine-containing beverages exceeding 500 mg caffeine/day (5 cups&#xD;
             of coffee) and the inability to refrain from the use of caffeine-containing beverages&#xD;
             during confinement in the Clinical Unit.&#xD;
&#xD;
         18. Excessive alcohol consumption (regular alcohol intake ≥21 units per week). Use of&#xD;
             alcohol 48 hours before any study visit, as confirmed by urine alcohol testing at&#xD;
             Screening, Day -2, and with any additional tests at the discretion of the PI.&#xD;
&#xD;
         19. History in the last year or presence of drug addiction (positive urine drug screen) at&#xD;
             Screening and Day -2.&#xD;
&#xD;
         20. Presence or history of alcohol abuse in the last year, as confirmed by subject's&#xD;
             general practitioner (GP).&#xD;
&#xD;
         21. Blood donation within 8 weeks before the first IMP administration.&#xD;
&#xD;
         22. Participation in another study with an experimental drug within 3 months before the&#xD;
             first dosing day.&#xD;
&#xD;
         23. Any psychological, emotional problems, any disorder or resultant therapy that was&#xD;
             likely to invalidate informed consent, or limited the ability of the subject to comply&#xD;
             with the protocol requirements.&#xD;
&#xD;
         24. Unlikely to comply with the protocol requirements, instructions and study-related&#xD;
             restrictions; e.g., uncooperative attitude, inability to return for Follow-up visits&#xD;
             and improbability of completing the clinical study.&#xD;
&#xD;
         25. Planned surgery, dental procedure, or hospitalisation from the Screening Visit until&#xD;
             the end of the study.&#xD;
&#xD;
         26. Inability to give written informed consent or to comply fully with the protocol.&#xD;
&#xD;
         27. Subjects who, in the opinion of the PI, were considered unsuitable for any other&#xD;
             reason.&#xD;
&#xD;
             -&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Annelize Koch, MBChB</last_name>
    <role>Principal Investigator</role>
    <affiliation>PAREXEL Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PAREXEL EPCU Northwick Park</name>
      <address>
        <city>Harrow</city>
        <state>Middlesex</state>
        <zip>HA1 3UJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 20, 2016</study_first_submitted>
  <study_first_submitted_qc>January 25, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 28, 2016</study_first_posted>
  <results_first_submitted>December 14, 2019</results_first_submitted>
  <results_first_submitted_qc>September 7, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">September 29, 2020</results_first_posted>
  <last_update_submitted>January 11, 2021</last_update_submitted>
  <last_update_submitted_qc>January 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>UVB Pain Model</keyword>
  <keyword>PK</keyword>
  <keyword>Topical</keyword>
  <keyword>NSAIDs</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ibuprofen</mesh_term>
    <mesh_term>Diclofenac</mesh_term>
    <mesh_term>Salicylates</mesh_term>
    <mesh_term>Methyl salicylate</mesh_term>
    <mesh_term>Menthol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Cohort 1 (Dosed on Days 1, 2 and 3)</title>
          <description>All Cohort 1 participants: Ibuprofen (day 1), TIB200 gel (10%, w/w) (Day 2) and TIB200 (placebo gel) (Day 3)&#xD;
(Follow up 7-9 days post last UVB irradiation)&#xD;
Ibuprofen: Single topical dose per 1.76 cm2 test site of: 22 microliters (μL) (20 ± l mg)* of TIB200 Gel (ibuprofen 10% w/w) (Test Gel) or 22 μL (20 ± l mg)* of matching placebo TIB200 Gel (placebo gel) or 22 μL (20 ± l mg)* of Nurofen Maximum Strength Gel (ibuprofen 10% w/w) (reference gel).</description>
        </group>
        <group group_id="P2">
          <title>Cohort 2 (Dosed on Days 1,2,3 and 4)</title>
          <description>All Cohort 2 Participants: Diclofenac, DCF100 gel (2% w/w) (day 1), DCF100 gel (4% w/w) (day 2), DCF100 gel (marching placebo) Day 3 and Voltarol® 12 Hour Emulgel® P 2.32% Gel (day 4)&#xD;
(Follow up 7-9 days post last UVB irradiation)&#xD;
Diclofenac: Subjects were randomised to receive 22 uL (20 ± l mg) DCF100 Gel (diclofenac 2% w/w) / DCF100 Gel (diclofenac 4% w/w) / Matching Placebo DCF100 Gel / Voltarol® 12 Hour Emulgel® P 2.32% Gel. The gels were administered topically on two test sites on the lower back of the subject, each 1.76 cm2 in size. The two test sites were UVB irradiated on the previous day, between 22 and 26 hours (24 ± 2 hours) before dosing.</description>
        </group>
        <group group_id="P3">
          <title>Cohort 3 (Dosed on Days 1 and 2)</title>
          <description>All Cohort 3 Participants: Methyl-salicylate / Menthol, SPR300 gel (15%:7%, w/w; ratio of Methylsalicylate / Menthol) (day 1) and SPR300 (Matching Placebo) (day 2)&#xD;
Follow up visit between days 7-9 post last UVB irradiation&#xD;
Methyl-salicylate / Menthol: Subjects were randomised to receive 22 uL (20 ± l mg) SPR300 Gel / Matching Placebo SPR300 Gel. The gels were administered topically on two test sites on the lower back of the subject, each 1.76cm2 in size. The two test sites were UVB irradiated on the previous day, between 22 and 26 hours (24 ± 2 hours) before dosing.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cohort 1</title>
          <description>Cohort 1:&#xD;
Ibuprofen: Single topical dose per 1.76 cm2 test site of: 22 microliters (μL) (20 ± l mg)* of TIB200 Gel (ibuprofen 10% w/w) (Test Gel) or 22 μL (20 ± l mg)* of matching placebo TIB200 Gel (placebo gel) or 22 μL (20 ± l mg)* of Nurofen Maximum Strength Gel (ibuprofen 10% w/w) (reference gel) or Ibuprofen, Nurofen oral tablets (2 x 400 mg)</description>
        </group>
        <group group_id="B2">
          <title>Cohort 2:</title>
          <description>Cohort 2:&#xD;
Diclofenac: Subjects were randomised to receive 22 uL (20 ± l mg) DCF100 Gel (diclofenac 2% w/w) / DCF100 Gel (diclofenac 4% w/w) / Matching Placebo DCF100 Gel / Voltarol® 12 Hour Emulgel® P 2.32% Gel. The gels were administered topically on two test sites on the lower back of the subject, each 1.76 cm2 in size. The two test sites were UVB irradiated on the previous day, between 22 and 26 hours (24 ± 2 hours) before dosing.</description>
        </group>
        <group group_id="B3">
          <title>Cohort 3</title>
          <description>Cohort 3:&#xD;
Methyl-salicylate / Menthol: Subjects were randomised to receive 22 uL (20 ± l mg) SPR300 Gel / Matching Placebo SPR300 Gel. The gels were administered topically on two test sites on the lower back of the subject, each 1.76cm2 in size. The two test sites were UVB irradiated on the previous day, between 22 and 26 hours (24 ± 2 hours) before dosing.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
            <count group_id="B2" value="20"/>
            <count group_id="B3" value="20"/>
            <count group_id="B4" value="60"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="60"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Heat Pain Tolerance Test (HPTT) Measured the Point at Which the Heat Became Painful - Degrees Centigrade -</title>
        <description>To assess the pharmacodynamic effect by Heat Pain Tolerance Test (HPTT) which measured the point at which the heat became painful (degrees centigrade) of three topical analgesics, DCF100, TIB200, and SPR300 versus topical placebo and active topical reference products in a model of UV-induced inflammatory pain.</description>
        <time_frame>15 minutes before to 6 hours post administration</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: TIB200 Gel 10%</title>
            <description>Cohort 1: Ibuprofen, TIB200 gel (10%, w/w)&#xD;
Ibuprofen: Single topical dose per 1.76 cm2 test site of: 22 microliters (μL) (20 ± l mg)* of TIB200 Gel (ibuprofen 10% w/w) (Test Gel) or 22 μL (20 ± l mg)* of matching placebo TIB200 Gel (placebo gel) or 22 μL (20 ± l mg)* of Nurofen Maximum Strength Gel (ibuprofen 10% w/w) (reference gel).</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1: Nurofen Gel 10%</title>
            <description>Cohort 1: Ibuprofen, Nurofen Max Strength gel (10%, w/w)&#xD;
Ibuprofen: Single topical dose per 1.76 cm2 test site of: 22 microliters (μL) (20 ± l mg)* of TIB200 Gel (ibuprofen 10% w/w) (Test Gel) or 22 μL (20 ± l mg)* of matching placebo TIB200 Gel (placebo gel) or 22 μL (20 ± l mg)* of Nurofen Maximum Strength Gel (ibuprofen 10% w/w) (reference gel).</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1: Nurofen Tablets</title>
            <description>Cohort 1: Ibuprofen, Nurofen oral tablets (2 x 400 mg)&#xD;
Ibuprofen: Single topical dose per 1.76 cm2 test site of: 22 microliters (μL) (20 ± l mg)* of TIB200 Gel (ibuprofen 10% w/w) (Test Gel) or 22 μL (20 ± l mg)* of matching placebo TIB200 Gel (placebo gel) or 22 μL (20 ± l mg)* of Nurofen Maximum Strength Gel (ibuprofen 10% w/w) (reference gel).</description>
          </group>
          <group group_id="O4">
            <title>Cohort 1: TIB200 Placebo Gel</title>
            <description>Cohort 1: TIB200 matching placebo gel&#xD;
Placebo: The placebo gels were administered topically on two test sites on the lower back of the subject, each 1.76 cm2 in size. The two test sites were UVB irradiated on the previous day, between 22 and 26 hours (24 ± 2 hours) before dosing.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 2: DCF100 Gel 2%</title>
            <description>Cohort 2: Diclofenac, DCF100 gel (2% w/w)&#xD;
Diclofenac: Subjects were randomised to receive 22 uL (20 ± l mg) DCF100 Gel (diclofenac 2% w/w) / DCF100 Gel (diclofenac 4% w/w) / Matching Placebo DCF100 Gel / Voltarol® 12 Hour Emulgel® P 2.32% Gel. The gels were administered topically on two test sites on the lower back of the subject, each 1.76 cm2 in size. The two test sites were UVB irradiated on the previous day, between 22 and 26 hours (24 ± 2 hours) before dosing.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 2: DCF100 Gel 4%</title>
            <description>Cohort 2: Diclofenac, DCF100 gel (4% w/w)&#xD;
Diclofenac: Subjects were randomised to receive 22 uL (20 ± l mg) DCF100 Gel (diclofenac 2% w/w) / DCF100 Gel (diclofenac 4% w/w) / Matching Placebo DCF100 Gel / Voltarol® 12 Hour Emulgel® P 2.32% Gel. The gels were administered topically on two test sites on the lower back of the subject, each 1.76 cm2 in size. The two test sites were UVB irradiated on the previous day, between 22 and 26 hours (24 ± 2 hours) before dosing.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 2: Voltaren Gel 2%</title>
            <description>Cohort 2: Diclofenac, Voltaren Emulgel (2%)&#xD;
Diclofenac: Subjects were randomised to receive 22 uL (20 ± l mg) DCF100 Gel (diclofenac 2% w/w) / DCF100 Gel (diclofenac 4% w/w) / Matching Placebo DCF100 Gel / Voltarol® 12 Hour Emulgel® P 2.32% Gel. The gels were administered topically on two test sites on the lower back of the subject, each 1.76 cm2 in size. The two test sites were UVB irradiated on the previous day, between 22 and 26 hours (24 ± 2 hours) before dosing.</description>
          </group>
          <group group_id="O8">
            <title>Cohort 2: Voltarol Oral Tablet</title>
            <description>Cohort 2: Diclofenac, Voltarol oral tablet (50 mg)&#xD;
Diclofenac: Subjects were randomised to receive 22 uL (20 ± l mg) DCF100 Gel (diclofenac 2% w/w) / DCF100 Gel (diclofenac 4% w/w) / Matching Placebo DCF100 Gel / Voltarol® 12 Hour Emulgel® P 2.32% Gel. The gels were administered topically on two test sites on the lower back of the subject, each 1.76 cm2 in size. The two test sites were UVB irradiated on the previous day, between 22 and 26 hours (24 ± 2 hours) before dosing.</description>
          </group>
          <group group_id="O9">
            <title>Cohort 2: DCF100 Placebo Gel</title>
            <description>Cohort 2: DCF100 matching placebo gel&#xD;
Placebo: The placebo gels were administered topically on two test sites on the lower back of the subject, each 1.76 cm2 in size. The two test sites were UVB irradiated on the previous day, between 22 and 26 hours (24 ± 2 hours) before dosing.</description>
          </group>
          <group group_id="O10">
            <title>Cohort 3: SPR300 Gel (15%:7%)</title>
            <description>Cohort 3: Methyl-salicylate / Menthol, SPR300 gel (15%:7%, w/w; ratio of Methylsalicylate / Menthol)&#xD;
Methyl-salicylate / Menthol: Subjects were randomised to receive 22 uL (20 ± l mg) SPR300 Gel / Matching Placebo SPR300 Gel. The gels were administered topically on two test sites on the lower back of the subject, each 1.76cm2 in size. The two test sites were UVB irradiated on the previous day, between 22 and 26 hours (24 ± 2 hours) before dosing.</description>
          </group>
          <group group_id="O11">
            <title>Cohort 3: SPR300 Placebo Gel</title>
            <description>Cohort 3: SPR300 matching placebo gel&#xD;
Placebo: The placebo gels were administered topically on two test sites on the lower back of the subject, each 1.76 cm2 in size. The two test sites were UVB irradiated on the previous day, between 22 and 26 hours (24 ± 2 hours) before dosing.</description>
          </group>
        </group_list>
        <measure>
          <title>Heat Pain Tolerance Test (HPTT) Measured the Point at Which the Heat Became Painful - Degrees Centigrade -</title>
          <description>To assess the pharmacodynamic effect by Heat Pain Tolerance Test (HPTT) which measured the point at which the heat became painful (degrees centigrade) of three topical analgesics, DCF100, TIB200, and SPR300 versus topical placebo and active topical reference products in a model of UV-induced inflammatory pain.</description>
          <units>Degrees Centigrade</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="20"/>
                <count group_id="O5" value="20"/>
                <count group_id="O6" value="20"/>
                <count group_id="O7" value="20"/>
                <count group_id="O8" value="20"/>
                <count group_id="O9" value="20"/>
                <count group_id="O10" value="20"/>
                <count group_id="O11" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3635" spread="1.0277"/>
                    <measurement group_id="O2" value="0.7358" spread="1.0277"/>
                    <measurement group_id="O3" value="0.0887" spread="0.9024"/>
                    <measurement group_id="O4" value="-0.1983" spread="0.4616"/>
                    <measurement group_id="O5" value="0.6679" spread="1.0657"/>
                    <measurement group_id="O6" value="0.8722" spread="1.0430"/>
                    <measurement group_id="O7" value="0.7978" spread="0.9780"/>
                    <measurement group_id="O8" value="0.6835" spread="0.7344"/>
                    <measurement group_id="O9" value="0.1688" spread="0.7231"/>
                    <measurement group_id="O10" value="0.3934" spread="1.2384"/>
                    <measurement group_id="O11" value="-0.0123" spread="1.0103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Intensity of the UVB-induced Erythema (Determined by Assessment of Skin Blood Flow by Laser Doppler Imaging [Flux Units])</title>
        <description>Intensity of the Ultra Violet B radiation (UVB)-induced erythema (determined by assessment of skin blood flow by laser Doppler imaging [flux units], up to 8 subjects per cohort) - Change from baseline</description>
        <time_frame>15 minutes before to 6 hours post administration</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: TIB200 Gel 10%</title>
            <description>Cohort 1: Ibuprofen, TIB200 gel (10%, w/w)&#xD;
Ibuprofen: Single topical dose per 1.76 cm2 test site of: 22 microliters (μL) (20 ± l mg)* of TIB200 Gel (ibuprofen 10% w/w) (Test Gel) or 22 μL (20 ± l mg)* of matching placebo TIB200 Gel (placebo gel) or 22 μL (20 ± l mg)* of Nurofen Maximum Strength Gel (ibuprofen 10% w/w) (reference gel).</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1: Nurofen Gel 10%</title>
            <description>Cohort 1: Ibuprofen, Nurofen Max Strength gel (10%, w/w)&#xD;
Ibuprofen: Single topical dose per 1.76 cm2 test site of: 22 microliters (μL) (20 ± l mg)* of TIB200 Gel (ibuprofen 10% w/w) (Test Gel) or 22 μL (20 ± l mg)* of matching placebo TIB200 Gel (placebo gel) or 22 μL (20 ± l mg)* of Nurofen Maximum Strength Gel (ibuprofen 10% w/w) (reference gel).</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1: Nurofen Tablets</title>
            <description>Cohort 1: Ibuprofen, Nurofen oral tablets (2 x 400 mg)&#xD;
Ibuprofen: Single topical dose per 1.76 cm2 test site of: 22 microliters (μL) (20 ± l mg)* of TIB200 Gel (ibuprofen 10% w/w) (Test Gel) or 22 μL (20 ± l mg)* of matching placebo TIB200 Gel (placebo gel) or 22 μL (20 ± l mg)* of Nurofen Maximum Strength Gel (ibuprofen 10% w/w) (reference gel).</description>
          </group>
          <group group_id="O4">
            <title>Cohort 1: TIB200 Placebo Gel</title>
            <description>Cohort 1: TIB200 matching placebo gel&#xD;
Placebo: The placebo gels were administered topically on two test sites on the lower back of the subject, each 1.76 cm2 in size. The two test sites were UVB irradiated on the previous day, between 22 and 26 hours (24 ± 2 hours) before dosing.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 2: DCF100 Gel 2%</title>
            <description>Cohort 2: Diclofenac, DCF100 gel (2% w/w)&#xD;
Diclofenac: Subjects were randomised to receive 22 uL (20 ± l mg) DCF100 Gel (diclofenac 2% w/w) / DCF100 Gel (diclofenac 4% w/w) / Matching Placebo DCF100 Gel / Voltarol® 12 Hour Emulgel® P 2.32% Gel. The gels were administered topically on two test sites on the lower back of the subject, each 1.76 cm2 in size. The two test sites were UVB irradiated on the previous day, between 22 and 26 hours (24 ± 2 hours) before dosing.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 2: DCF100 Gel 4%</title>
            <description>Cohort 2: Diclofenac, DCF100 gel (4% w/w)&#xD;
Diclofenac: Subjects were randomised to receive 22 uL (20 ± l mg) DCF100 Gel (diclofenac 2% w/w) / DCF100 Gel (diclofenac 4% w/w) / Matching Placebo DCF100 Gel / Voltarol® 12 Hour Emulgel® P 2.32% Gel. The gels were administered topically on two test sites on the lower back of the subject, each 1.76 cm2 in size. The two test sites were UVB irradiated on the previous day, between 22 and 26 hours (24 ± 2 hours) before dosing.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 2: Voltaren Gel 2%</title>
            <description>Cohort 2: Diclofenac, Voltaren Emulgel (2%)&#xD;
Diclofenac: Subjects were randomised to receive 22 uL (20 ± l mg) DCF100 Gel (diclofenac 2% w/w) / DCF100 Gel (diclofenac 4% w/w) / Matching Placebo DCF100 Gel / Voltarol® 12 Hour Emulgel® P 2.32% Gel. The gels were administered topically on two test sites on the lower back of the subject, each 1.76 cm2 in size. The two test sites were UVB irradiated on the previous day, between 22 and 26 hours (24 ± 2 hours) before dosing.</description>
          </group>
          <group group_id="O8">
            <title>Cohort 2: Voltarol Oral Tablet</title>
            <description>Cohort 2: Diclofenac, Voltarol oral tablet (50 mg)&#xD;
Diclofenac: Subjects were randomised to receive 22 uL (20 ± l mg) DCF100 Gel (diclofenac 2% w/w) / DCF100 Gel (diclofenac 4% w/w) / Matching Placebo DCF100 Gel / Voltarol® 12 Hour Emulgel® P 2.32% Gel. The gels were administered topically on two test sites on the lower back of the subject, each 1.76 cm2 in size. The two test sites were UVB irradiated on the previous day, between 22 and 26 hours (24 ± 2 hours) before dosing.</description>
          </group>
          <group group_id="O9">
            <title>Cohort 2: DCF100 Placebo Gel</title>
            <description>Cohort 2: DCF100 matching placebo gel&#xD;
Placebo: The placebo gels were administered topically on two test sites on the lower back of the subject, each 1.76 cm2 in size. The two test sites were UVB irradiated on the previous day, between 22 and 26 hours (24 ± 2 hours) before dosing.</description>
          </group>
          <group group_id="O10">
            <title>Cohort 3: SPR300 Gel (15%:7%)</title>
            <description>Cohort 3: Methyl-salicylate / Menthol, SPR300 gel (15%:7%, w/w; ratio of Methylsalicylate / Menthol)&#xD;
Methyl-salicylate / Menthol: Subjects were randomised to receive 22 uL (20 ± l mg) SPR300 Gel / Matching Placebo SPR300 Gel. The gels were administered topically on two test sites on the lower back of the subject, each 1.76cm2 in size. The two test sites were UVB irradiated on the previous day, between 22 and 26 hours (24 ± 2 hours) before dosing.</description>
          </group>
          <group group_id="O11">
            <title>Cohort 3: SPR300 Placebo Gel</title>
            <description>Cohort 3: SPR300 matching placebo gel&#xD;
Placebo: The placebo gels were administered topically on two test sites on the lower back of the subject, each 1.76 cm2 in size. The two test sites were UVB irradiated on the previous day, between 22 and 26 hours (24 ± 2 hours) before dosing.</description>
          </group>
        </group_list>
        <measure>
          <title>Intensity of the UVB-induced Erythema (Determined by Assessment of Skin Blood Flow by Laser Doppler Imaging [Flux Units])</title>
          <description>Intensity of the Ultra Violet B radiation (UVB)-induced erythema (determined by assessment of skin blood flow by laser Doppler imaging [flux units], up to 8 subjects per cohort) - Change from baseline</description>
          <units>Laser doppler imaging (Flux Units)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="8"/>
                <count group_id="O9" value="8"/>
                <count group_id="O10" value="8"/>
                <count group_id="O11" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-313.3879" spread="105.7042"/>
                    <measurement group_id="O2" value="-171.5589" spread="96.6485"/>
                    <measurement group_id="O3" value="-262.0693" spread="88.5449"/>
                    <measurement group_id="O4" value="-95.3974" spread="81.4103"/>
                    <measurement group_id="O5" value="-228.3016" spread="183.2260"/>
                    <measurement group_id="O6" value="-278.1918" spread="103.7333"/>
                    <measurement group_id="O7" value="-198.1408" spread="133.2886"/>
                    <measurement group_id="O8" value="-198.1408" spread="211.2754"/>
                    <measurement group_id="O9" value="-45.376" spread="104.4476"/>
                    <measurement group_id="O10" value="12.2265" spread="111.1065"/>
                    <measurement group_id="O11" value="67.3931" spread="91.092"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak Plasma Concentration (Cmax)</title>
        <description>Maximum observed plasma concentration (Cmax), time corresponding to occurrence of Cmax (tmax) (up to 6 subjects per cohort only) laser Doppler imaging [flux units], up to 6 subjects per cohort)</description>
        <time_frame>15 minutes before and 1, 2, 4 and 6 hours post administration</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: TIB200 Gel 10%</title>
            <description>Cohort 1: Ibuprofen, TIB200 gel (10%, w/w)&#xD;
Ibuprofen: Single topical dose per 1.76 cm2 test site of: 22 microliters (μL) (20 ± l mg)* of TIB200 Gel (ibuprofen 10% w/w) (Test Gel) or 22 μL (20 ± l mg)* of matching placebo TIB200 Gel (placebo gel) or 22 μL (20 ± l mg)* of Nurofen Maximum Strength Gel (ibuprofen 10% w/w) (reference gel).</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1: Nurofen Gel 10%</title>
            <description>Cohort 1: Ibuprofen, Nurofen Max Strength gel (10%, w/w)&#xD;
Ibuprofen: Single topical dose per 1.76 cm2 test site of: 22 microliters (μL) (20 ± l mg)* of TIB200 Gel (ibuprofen 10% w/w) (Test Gel) or 22 μL (20 ± l mg)* of matching placebo TIB200 Gel (placebo gel) or 22 μL (20 ± l mg)* of Nurofen Maximum Strength Gel (ibuprofen 10% w/w) (reference gel).</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1: Nurofen Tablets</title>
            <description>Cohort 1: Ibuprofen, Nurofen oral tablets (2 x 400 mg)&#xD;
Ibuprofen: Single topical dose per 1.76 cm2 test site of: 22 microliters (μL) (20 ± l mg)* of TIB200 Gel (ibuprofen 10% w/w) (Test Gel) or 22 μL (20 ± l mg)* of matching placebo TIB200 Gel (placebo gel) or 22 μL (20 ± l mg)* of Nurofen Maximum Strength Gel (ibuprofen 10% w/w) (reference gel).</description>
          </group>
          <group group_id="O4">
            <title>Cohort 2: DCF100 Gel 2%</title>
            <description>Cohort 2: Diclofenac, DCF100 gel (2% w/w)&#xD;
Diclofenac: Subjects were randomised to receive 22 uL (20 ± l mg) DCF100 Gel (diclofenac 2% w/w) / DCF100 Gel (diclofenac 4% w/w) / Matching Placebo DCF100 Gel / Voltarol® 12 Hour Emulgel® P 2.32% Gel. The gels were administered topically on two test sites on the lower back of the subject, each 1.76 cm2 in size. The two test sites were UVB irradiated on the previous day, between 22 and 26 hours (24 ± 2 hours) before dosing.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 2: DCF100 Gel 4%</title>
            <description>Cohort 2: Diclofenac, DCF100 gel (4% w/w)&#xD;
Diclofenac: Subjects were randomised to receive 22 uL (20 ± l mg) DCF100 Gel (diclofenac 2% w/w) / DCF100 Gel (diclofenac 4% w/w) / Matching Placebo DCF100 Gel / Voltarol® 12 Hour Emulgel® P 2.32% Gel. The gels were administered topically on two test sites on the lower back of the subject, each 1.76 cm2 in size. The two test sites were UVB irradiated on the previous day, between 22 and 26 hours (24 ± 2 hours) before dosing.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 2: Voltaren Gel 2%</title>
            <description>Cohort 2: Diclofenac, Voltaren Emulgel (2%)&#xD;
Diclofenac: Subjects were randomised to receive 22 uL (20 ± l mg) DCF100 Gel (diclofenac 2% w/w) / DCF100 Gel (diclofenac 4% w/w) / Matching Placebo DCF100 Gel / Voltarol® 12 Hour Emulgel® P 2.32% Gel. The gels were administered topically on two test sites on the lower back of the subject, each 1.76 cm2 in size. The two test sites were UVB irradiated on the previous day, between 22 and 26 hours (24 ± 2 hours) before dosing.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 2: Voltarol Oral Tablet</title>
            <description>Cohort 2: Diclofenac, Voltarol oral tablet (50 mg)&#xD;
Diclofenac: Subjects were randomised to receive 22 uL (20 ± l mg) DCF100 Gel (diclofenac 2% w/w) / DCF100 Gel (diclofenac 4% w/w) / Matching Placebo DCF100 Gel / Voltarol® 12 Hour Emulgel® P 2.32% Gel. The gels were administered topically on two test sites on the lower back of the subject, each 1.76 cm2 in size. The two test sites were UVB irradiated on the previous day, between 22 and 26 hours (24 ± 2 hours) before dosing.</description>
          </group>
          <group group_id="O8">
            <title>Cohort 3: SPR300 Gel (15%:7%)</title>
            <description>Cohort 3: Methyl-salicylate / Menthol, SPR300 gel (15%:7%, w/w; ratio of Methylsalicylate / Menthol)&#xD;
Methyl-salicylate / Menthol: Subjects were randomised to receive 22 uL (20 ± l mg) SPR300 Gel / Matching Placebo SPR300 Gel. The gels were administered topically on two test sites on the lower back of the subject, each 1.76cm2 in size. The two test sites were UVB irradiated on the previous day, between 22 and 26 hours (24 ± 2 hours) before dosing.</description>
          </group>
          <group group_id="O9">
            <title>Cohort 3: SPR300 Placebo Gel</title>
            <description>Cohort 3: SPR300 matching placebo gel&#xD;
Placebo: The placebo gels were administered topically on two test sites on the lower back of the subject, each 1.76 cm2 in size. The two test sites were UVB irradiated on the previous day, between 22 and 26 hours (24 ± 2 hours) before dosing.</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Plasma Concentration (Cmax)</title>
          <description>Maximum observed plasma concentration (Cmax), time corresponding to occurrence of Cmax (tmax) (up to 6 subjects per cohort only) laser Doppler imaging [flux units], up to 6 subjects per cohort)</description>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="8"/>
                <count group_id="O9" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.5" spread="14"/>
                    <measurement group_id="O2" value="5.15" spread="8.1"/>
                    <measurement group_id="O3" value="29900" spread="5490"/>
                    <measurement group_id="O4" value="0" spread="0"/>
                    <measurement group_id="O5" value="0" spread="0"/>
                    <measurement group_id="O6" value="0" spread="0"/>
                    <measurement group_id="O7" value="772" spread="468"/>
                    <measurement group_id="O8" value="0" spread="0"/>
                    <measurement group_id="O9" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Plasma Concentration Versus Time Curve</title>
        <description>Area under the concentration vs. time curve from time zero to 6 hours (AUC0-6h) (up to 6 subjects per cohort only) laser Doppler imaging [flux units], up to 6 subjects per cohort)</description>
        <time_frame>15 minutes before and 1, 2, 4 and 6 hours post administration</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: TIB200 Gel 10%</title>
            <description>Cohort 1: Ibuprofen, TIB200 gel (10%, w/w)&#xD;
Ibuprofen: Single topical dose per 1.76 cm2 test site of: 22 microliters (μL) (20 ± l mg)* of TIB200 Gel (ibuprofen 10% w/w) (Test Gel) or 22 μL (20 ± l mg)* of matching placebo TIB200 Gel (placebo gel) or 22 μL (20 ± l mg)* of Nurofen Maximum Strength Gel (ibuprofen 10% w/w) (reference gel).</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1: Nurofen Gel 10%</title>
            <description>Cohort 1: Ibuprofen, Nurofen Max Strength gel (10%, w/w)&#xD;
Ibuprofen: Single topical dose per 1.76 cm2 test site of: 22 microliters (μL) (20 ± l mg)* of TIB200 Gel (ibuprofen 10% w/w) (Test Gel) or 22 μL (20 ± l mg)* of matching placebo TIB200 Gel (placebo gel) or 22 μL (20 ± l mg)* of Nurofen Maximum Strength Gel (ibuprofen 10% w/w) (reference gel).</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1: Nurofen Tablets</title>
            <description>Cohort 1: Ibuprofen, Nurofen oral tablets (2 x 400 mg)&#xD;
Ibuprofen: Single topical dose per 1.76 cm2 test site of: 22 microliters (μL) (20 ± l mg)* of TIB200 Gel (ibuprofen 10% w/w) (Test Gel) or 22 μL (20 ± l mg)* of matching placebo TIB200 Gel (placebo gel) or 22 μL (20 ± l mg)* of Nurofen Maximum Strength Gel (ibuprofen 10% w/w) (reference gel).</description>
          </group>
          <group group_id="O4">
            <title>Cohort 2: DCF100 Gel 2%</title>
            <description>Cohort 2: Diclofenac, DCF100 gel (2% w/w)&#xD;
Diclofenac: Subjects were randomised to receive 22 uL (20 ± l mg) DCF100 Gel (diclofenac 2% w/w) / DCF100 Gel (diclofenac 4% w/w) / Matching Placebo DCF100 Gel / Voltarol® 12 Hour Emulgel® P 2.32% Gel. The gels were administered topically on two test sites on the lower back of the subject, each 1.76 cm2 in size. The two test sites were UVB irradiated on the previous day, between 22 and 26 hours (24 ± 2 hours) before dosing.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 2: DCF100 Gel 4%</title>
            <description>Cohort 2: Diclofenac, DCF100 gel (4% w/w)&#xD;
Diclofenac: Subjects were randomised to receive 22 uL (20 ± l mg) DCF100 Gel (diclofenac 2% w/w) / DCF100 Gel (diclofenac 4% w/w) / Matching Placebo DCF100 Gel / Voltarol® 12 Hour Emulgel® P 2.32% Gel. The gels were administered topically on two test sites on the lower back of the subject, each 1.76 cm2 in size. The two test sites were UVB irradiated on the previous day, between 22 and 26 hours (24 ± 2 hours) before dosing.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 2: Voltaren Gel 2%</title>
            <description>Cohort 2: Diclofenac, Voltaren Emulgel (2%)&#xD;
Diclofenac: Subjects were randomised to receive 22 uL (20 ± l mg) DCF100 Gel (diclofenac 2% w/w) / DCF100 Gel (diclofenac 4% w/w) / Matching Placebo DCF100 Gel / Voltarol® 12 Hour Emulgel® P 2.32% Gel. The gels were administered topically on two test sites on the lower back of the subject, each 1.76 cm2 in size. The two test sites were UVB irradiated on the previous day, between 22 and 26 hours (24 ± 2 hours) before dosing.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 2: Voltarol Oral Tablet</title>
            <description>Cohort 2: Diclofenac, Voltarol oral tablet (50 mg)&#xD;
Diclofenac: Subjects were randomised to receive 22 uL (20 ± l mg) DCF100 Gel (diclofenac 2% w/w) / DCF100 Gel (diclofenac 4% w/w) / Matching Placebo DCF100 Gel / Voltarol® 12 Hour Emulgel® P 2.32% Gel. The gels were administered topically on two test sites on the lower back of the subject, each 1.76 cm2 in size. The two test sites were UVB irradiated on the previous day, between 22 and 26 hours (24 ± 2 hours) before dosing.</description>
          </group>
          <group group_id="O8">
            <title>Cohort 3: SPR300 Gel (15%:7%)</title>
            <description>Cohort 3: Methyl-salicylate / Menthol, SPR300 gel (15%:7%, w/w; ratio of Methylsalicylate / Menthol)&#xD;
Methyl-salicylate / Menthol: Subjects were randomised to receive 22 uL (20 ± l mg) SPR300 Gel / Matching Placebo SPR300 Gel. The gels were administered topically on two test sites on the lower back of the subject, each 1.76cm2 in size. The two test sites were UVB irradiated on the previous day, between 22 and 26 hours (24 ± 2 hours) before dosing.</description>
          </group>
          <group group_id="O9">
            <title>Cohort 3: SPR300 Placebo Gel</title>
            <description>Cohort 3: SPR300 matching placebo gel&#xD;
Placebo: The placebo gels were administered topically on two test sites on the lower back of the subject, each 1.76 cm2 in size. The two test sites were UVB irradiated on the previous day, between 22 and 26 hours (24 ± 2 hours) before dosing.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration Versus Time Curve</title>
          <description>Area under the concentration vs. time curve from time zero to 6 hours (AUC0-6h) (up to 6 subjects per cohort only) laser Doppler imaging [flux units], up to 6 subjects per cohort)</description>
          <units>h*ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="8"/>
                <count group_id="O9" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.7" spread="64.3"/>
                    <measurement group_id="O2" value="19.9" spread="33.7"/>
                    <measurement group_id="O3" value="90000" spread="15400"/>
                    <measurement group_id="O4" value="0" spread="0"/>
                    <measurement group_id="O5" value="0" spread="0"/>
                    <measurement group_id="O6" value="0" spread="0"/>
                    <measurement group_id="O7" value="1030" spread="463"/>
                    <measurement group_id="O8" value="0" spread="0"/>
                    <measurement group_id="O9" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Recorded Abnormal Clinical Assessments</title>
        <description>Laboratory assessments - standard clinical trial assessments for clinical chemistry and haematology&#xD;
Listing of individual laboratory measurements by subjects and evaluation of each laboratory parameter</description>
        <time_frame>Estimated study duration for each subject will be approximately 6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: TIB200 Gel 10%</title>
            <description>Cohort 1: Ibuprofen, TIB200 gel (10%, w/w)&#xD;
Ibuprofen: Single topical dose per 1.76 cm2 test site of: 22 microliters (μL) (20 ± l mg)* of TIB200 Gel (ibuprofen 10% w/w) (Test Gel) or 22 μL (20 ± l mg)* of matching placebo TIB200 Gel (placebo gel) or 22 μL (20 ± l mg)* of Nurofen Maximum Strength Gel (ibuprofen 10% w/w) (reference gel).</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1: Nurofen Gel 10%</title>
            <description>Cohort 1: Ibuprofen, Nurofen Max Strength gel (10%, w/w)&#xD;
Ibuprofen: Single topical dose per 1.76 cm2 test site of: 22 microliters (μL) (20 ± l mg)* of TIB200 Gel (ibuprofen 10% w/w) (Test Gel) or 22 μL (20 ± l mg)* of matching placebo TIB200 Gel (placebo gel) or 22 μL (20 ± l mg)* of Nurofen Maximum Strength Gel (ibuprofen 10% w/w) (reference gel).</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1: Nurofen Tablets</title>
            <description>Cohort 1: Ibuprofen, Nurofen oral tablets (2 x 400 mg)&#xD;
Ibuprofen: Single topical dose per 1.76 cm2 test site of: 22 microliters (μL) (20 ± l mg)* of TIB200 Gel (ibuprofen 10% w/w) (Test Gel) or 22 μL (20 ± l mg)* of matching placebo TIB200 Gel (placebo gel) or 22 μL (20 ± l mg)* of Nurofen Maximum Strength Gel (ibuprofen 10% w/w) (reference gel).</description>
          </group>
          <group group_id="O4">
            <title>Cohort 1: TIB200 Placebo Gel</title>
            <description>Cohort 1: TIB200 matching placebo gel&#xD;
Placebo: The placebo gels were administered topically on two test sites on the lower back of the subject, each 1.76 cm2 in size. The two test sites were UVB irradiated on the previous day, between 22 and 26 hours (24 ± 2 hours) before dosing.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 2: DCF100 Gel 2%</title>
            <description>Cohort 2: Diclofenac, DCF100 gel (2% w/w)&#xD;
Diclofenac: Subjects were randomised to receive 22 uL (20 ± l mg) DCF100 Gel (diclofenac 2% w/w) / DCF100 Gel (diclofenac 4% w/w) / Matching Placebo DCF100 Gel / Voltarol® 12 Hour Emulgel® P 2.32% Gel. The gels were administered topically on two test sites on the lower back of the subject, each 1.76 cm2 in size. The two test sites were UVB irradiated on the previous day, between 22 and 26 hours (24 ± 2 hours) before dosing.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 2: DCF100 Gel 4%</title>
            <description>Cohort 2: Diclofenac, DCF100 gel (4% w/w)&#xD;
Diclofenac: Subjects were randomised to receive 22 uL (20 ± l mg) DCF100 Gel (diclofenac 2% w/w) / DCF100 Gel (diclofenac 4% w/w) / Matching Placebo DCF100 Gel / Voltarol® 12 Hour Emulgel® P 2.32% Gel. The gels were administered topically on two test sites on the lower back of the subject, each 1.76 cm2 in size. The two test sites were UVB irradiated on the previous day, between 22 and 26 hours (24 ± 2 hours) before dosing.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 2: Voltaren Gel 2%</title>
            <description>Cohort 2: Diclofenac, Voltaren Emulgel (2%)&#xD;
Diclofenac: Subjects were randomised to receive 22 uL (20 ± l mg) DCF100 Gel (diclofenac 2% w/w) / DCF100 Gel (diclofenac 4% w/w) / Matching Placebo DCF100 Gel / Voltarol® 12 Hour Emulgel® P 2.32% Gel. The gels were administered topically on two test sites on the lower back of the subject, each 1.76 cm2 in size. The two test sites were UVB irradiated on the previous day, between 22 and 26 hours (24 ± 2 hours) before dosing.</description>
          </group>
          <group group_id="O8">
            <title>Cohort 2: Voltarol Oral Tablet</title>
            <description>Cohort 2: Diclofenac, Voltarol oral tablet (50 mg)&#xD;
Diclofenac: Subjects were randomised to receive 22 uL (20 ± l mg) DCF100 Gel (diclofenac 2% w/w) / DCF100 Gel (diclofenac 4% w/w) / Matching Placebo DCF100 Gel / Voltarol® 12 Hour Emulgel® P 2.32% Gel. The gels were administered topically on two test sites on the lower back of the subject, each 1.76 cm2 in size. The two test sites were UVB irradiated on the previous day, between 22 and 26 hours (24 ± 2 hours) before dosing.</description>
          </group>
          <group group_id="O9">
            <title>Cohort 2: DCF100 Placebo Gel</title>
            <description>Cohort 2: DCF100 matching placebo gel&#xD;
Placebo: The placebo gels were administered topically on two test sites on the lower back of the subject, each 1.76 cm2 in size. The two test sites were UVB irradiated on the previous day, between 22 and 26 hours (24 ± 2 hours) before dosing.</description>
          </group>
          <group group_id="O10">
            <title>Cohort 3: SPR300 Gel (15%:7%)</title>
            <description>Cohort 3: Methyl-salicylate / Menthol, SPR300 gel (15%:7%, w/w; ratio of Methylsalicylate / Menthol)&#xD;
Methyl-salicylate / Menthol: Subjects were randomised to receive 22 uL (20 ± l mg) SPR300 Gel / Matching Placebo SPR300 Gel. The gels were administered topically on two test sites on the lower back of the subject, each 1.76cm2 in size. The two test sites were UVB irradiated on the previous day, between 22 and 26 hours (24 ± 2 hours) before dosing.</description>
          </group>
          <group group_id="O11">
            <title>Cohort 3: SPR300 Placebo Gel</title>
            <description>Cohort 3: SPR300 matching placebo gel&#xD;
Placebo: The placebo gels were administered topically on two test sites on the lower back of the subject, each 1.76 cm2 in size. The two test sites were UVB irradiated on the previous day, between 22 and 26 hours (24 ± 2 hours) before dosing.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Recorded Abnormal Clinical Assessments</title>
          <description>Laboratory assessments - standard clinical trial assessments for clinical chemistry and haematology&#xD;
Listing of individual laboratory measurements by subjects and evaluation of each laboratory parameter</description>
          <units>Assessments</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="20"/>
                <count group_id="O5" value="20"/>
                <count group_id="O6" value="20"/>
                <count group_id="O7" value="20"/>
                <count group_id="O8" value="20"/>
                <count group_id="O9" value="20"/>
                <count group_id="O10" value="20"/>
                <count group_id="O11" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Physical Exams to Ensure Safety and Well Being of the Subjects</title>
        <description>Physical examinations - including assessments of the application site. examination.</description>
        <time_frame>Estimated study duration for each subject will be approximately 6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: TIB200 Gel 10%</title>
            <description>Cohort 1: Ibuprofen, TIB200 gel (10%, w/w)&#xD;
Ibuprofen: Single topical dose per 1.76 cm2 test site of: 22 microliters (μL) (20 ± l mg)* of TIB200 Gel (ibuprofen 10% w/w) (Test Gel) or 22 μL (20 ± l mg)* of matching placebo TIB200 Gel (placebo gel) or 22 μL (20 ± l mg)* of Nurofen Maximum Strength Gel (ibuprofen 10% w/w) (reference gel).</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1: Nurofen Gel 10%</title>
            <description>Cohort 1: Ibuprofen, Nurofen Max Strength gel (10%, w/w)&#xD;
Ibuprofen: Single topical dose per 1.76 cm2 test site of: 22 microliters (μL) (20 ± l mg)* of TIB200 Gel (ibuprofen 10% w/w) (Test Gel) or 22 μL (20 ± l mg)* of matching placebo TIB200 Gel (placebo gel) or 22 μL (20 ± l mg)* of Nurofen Maximum Strength Gel (ibuprofen 10% w/w) (reference gel).</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1: Nurofen Tablets</title>
            <description>Cohort 1: Ibuprofen, Nurofen oral tablets (2 x 400 mg)&#xD;
Ibuprofen: Single topical dose per 1.76 cm2 test site of: 22 microliters (μL) (20 ± l mg)* of TIB200 Gel (ibuprofen 10% w/w) (Test Gel) or 22 μL (20 ± l mg)* of matching placebo TIB200 Gel (placebo gel) or 22 μL (20 ± l mg)* of Nurofen Maximum Strength Gel (ibuprofen 10% w/w) (reference gel).</description>
          </group>
          <group group_id="O4">
            <title>Cohort 1: TIB200 Placebo Gel</title>
            <description>Cohort 1: TIB200 matching placebo gel&#xD;
Placebo: The placebo gels were administered topically on two test sites on the lower back of the subject, each 1.76 cm2 in size. The two test sites were UVB irradiated on the previous day, between 22 and 26 hours (24 ± 2 hours) before dosing.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 2: DCF100 Gel 2%</title>
            <description>Cohort 2: Diclofenac, DCF100 gel (2% w/w)&#xD;
Diclofenac: Subjects were randomised to receive 22 uL (20 ± l mg) DCF100 Gel (diclofenac 2% w/w) / DCF100 Gel (diclofenac 4% w/w) / Matching Placebo DCF100 Gel / Voltarol® 12 Hour Emulgel® P 2.32% Gel. The gels were administered topically on two test sites on the lower back of the subject, each 1.76 cm2 in size. The two test sites were UVB irradiated on the previous day, between 22 and 26 hours (24 ± 2 hours) before dosing.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 2: DCF100 Gel 4%</title>
            <description>Cohort 2: Diclofenac, DCF100 gel (4% w/w)&#xD;
Diclofenac: Subjects were randomised to receive 22 uL (20 ± l mg) DCF100 Gel (diclofenac 2% w/w) / DCF100 Gel (diclofenac 4% w/w) / Matching Placebo DCF100 Gel / Voltarol® 12 Hour Emulgel® P 2.32% Gel. The gels were administered topically on two test sites on the lower back of the subject, each 1.76 cm2 in size. The two test sites were UVB irradiated on the previous day, between 22 and 26 hours (24 ± 2 hours) before dosing.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 2: Voltaren Gel 2%</title>
            <description>Cohort 2: Diclofenac, Voltaren Emulgel (2%)&#xD;
Diclofenac: Subjects were randomised to receive 22 uL (20 ± l mg) DCF100 Gel (diclofenac 2% w/w) / DCF100 Gel (diclofenac 4% w/w) / Matching Placebo DCF100 Gel / Voltarol® 12 Hour Emulgel® P 2.32% Gel. The gels were administered topically on two test sites on the lower back of the subject, each 1.76 cm2 in size. The two test sites were UVB irradiated on the previous day, between 22 and 26 hours (24 ± 2 hours) before dosing.</description>
          </group>
          <group group_id="O8">
            <title>Cohort 2: Voltarol Oral Tablet</title>
            <description>Cohort 2: Diclofenac, Voltarol oral tablet (50 mg)&#xD;
Diclofenac: Subjects were randomised to receive 22 uL (20 ± l mg) DCF100 Gel (diclofenac 2% w/w) / DCF100 Gel (diclofenac 4% w/w) / Matching Placebo DCF100 Gel / Voltarol® 12 Hour Emulgel® P 2.32% Gel. The gels were administered topically on two test sites on the lower back of the subject, each 1.76 cm2 in size. The two test sites were UVB irradiated on the previous day, between 22 and 26 hours (24 ± 2 hours) before dosing.</description>
          </group>
          <group group_id="O9">
            <title>Cohort 2: DCF100 Placebo Gel</title>
            <description>Cohort 2: DCF100 matching placebo gel&#xD;
Placebo: The placebo gels were administered topically on two test sites on the lower back of the subject, each 1.76 cm2 in size. The two test sites were UVB irradiated on the previous day, between 22 and 26 hours (24 ± 2 hours) before dosing.</description>
          </group>
          <group group_id="O10">
            <title>Cohort 3: SPR300 Gel (15%:7%)</title>
            <description>Cohort 3: Methyl-salicylate / Menthol, SPR300 gel (15%:7%, w/w; ratio of Methylsalicylate / Menthol)&#xD;
Methyl-salicylate / Menthol: Subjects were randomised to receive 22 uL (20 ± l mg) SPR300 Gel / Matching Placebo SPR300 Gel. The gels were administered topically on two test sites on the lower back of the subject, each 1.76cm2 in size. The two test sites were UVB irradiated on the previous day, between 22 and 26 hours (24 ± 2 hours) before dosing.</description>
          </group>
          <group group_id="O11">
            <title>Cohort 3: SPR300 Placebo Gel</title>
            <description>Cohort 3: SPR300 matching placebo gel&#xD;
Placebo: The placebo gels were administered topically on two test sites on the lower back of the subject, each 1.76 cm2 in size. The two test sites were UVB irradiated on the previous day, between 22 and 26 hours (24 ± 2 hours) before dosing.</description>
          </group>
        </group_list>
        <measure>
          <title>Physical Exams to Ensure Safety and Well Being of the Subjects</title>
          <description>Physical examinations - including assessments of the application site. examination.</description>
          <units>Abnormalities</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="20"/>
                <count group_id="O5" value="20"/>
                <count group_id="O6" value="20"/>
                <count group_id="O7" value="20"/>
                <count group_id="O8" value="20"/>
                <count group_id="O9" value="20"/>
                <count group_id="O10" value="20"/>
                <count group_id="O11" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Events (AEs)</title>
        <description>Local and systemic Adverse Events (AEs).</description>
        <time_frame>Estimated study duration for each subject will be approximately 6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: TIB200 Gel 10%</title>
            <description>Cohort 1: Ibuprofen, TIB200 gel (10%, w/w)&#xD;
Ibuprofen: Single topical dose per 1.76 cm2 test site of: 22 microliters (μL) (20 ± l mg)* of TIB200 Gel (ibuprofen 10% w/w) (Test Gel) or 22 μL (20 ± l mg)* of matching placebo TIB200 Gel (placebo gel) or 22 μL (20 ± l mg)* of Nurofen Maximum Strength Gel (ibuprofen 10% w/w) (reference gel).</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1: Nurofen Gel 10%</title>
            <description>Cohort 1: Ibuprofen, Nurofen Max Strength gel (10%, w/w)&#xD;
Ibuprofen: Single topical dose per 1.76 cm2 test site of: 22 microliters (μL) (20 ± l mg)* of TIB200 Gel (ibuprofen 10% w/w) (Test Gel) or 22 μL (20 ± l mg)* of matching placebo TIB200 Gel (placebo gel) or 22 μL (20 ± l mg)* of Nurofen Maximum Strength Gel (ibuprofen 10% w/w) (reference gel).</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1: Nurofen Tablets</title>
            <description>Cohort 1: Ibuprofen, Nurofen oral tablets (2 x 400 mg)&#xD;
Ibuprofen: Single topical dose per 1.76 cm2 test site of: 22 microliters (μL) (20 ± l mg)* of TIB200 Gel (ibuprofen 10% w/w) (Test Gel) or 22 μL (20 ± l mg)* of matching placebo TIB200 Gel (placebo gel) or 22 μL (20 ± l mg)* of Nurofen Maximum Strength Gel (ibuprofen 10% w/w) (reference gel).</description>
          </group>
          <group group_id="O4">
            <title>Cohort 1: TIB200 Placebo Gel</title>
            <description>Cohort 1: TIB200 matching placebo gel&#xD;
Placebo: The placebo gels were administered topically on two test sites on the lower back of the subject, each 1.76 cm2 in size. The two test sites were UVB irradiated on the previous day, between 22 and 26 hours (24 ± 2 hours) before dosing.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 2: DCF100 Gel 2%</title>
            <description>Cohort 2: Diclofenac, DCF100 gel (2% w/w)&#xD;
Diclofenac: Subjects were randomised to receive 22 uL (20 ± l mg) DCF100 Gel (diclofenac 2% w/w) / DCF100 Gel (diclofenac 4% w/w) / Matching Placebo DCF100 Gel / Voltarol® 12 Hour Emulgel® P 2.32% Gel. The gels were administered topically on two test sites on the lower back of the subject, each 1.76 cm2 in size. The two test sites were UVB irradiated on the previous day, between 22 and 26 hours (24 ± 2 hours) before dosing.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 2: DCF100 Gel 4%</title>
            <description>Cohort 2: Diclofenac, DCF100 gel (4% w/w)&#xD;
Diclofenac: Subjects were randomised to receive 22 uL (20 ± l mg) DCF100 Gel (diclofenac 2% w/w) / DCF100 Gel (diclofenac 4% w/w) / Matching Placebo DCF100 Gel / Voltarol® 12 Hour Emulgel® P 2.32% Gel. The gels were administered topically on two test sites on the lower back of the subject, each 1.76 cm2 in size. The two test sites were UVB irradiated on the previous day, between 22 and 26 hours (24 ± 2 hours) before dosing.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 2: Voltaren Gel 2%</title>
            <description>Cohort 2: Diclofenac, Voltaren Emulgel (2%)&#xD;
Diclofenac: Subjects were randomised to receive 22 uL (20 ± l mg) DCF100 Gel (diclofenac 2% w/w) / DCF100 Gel (diclofenac 4% w/w) / Matching Placebo DCF100 Gel / Voltarol® 12 Hour Emulgel® P 2.32% Gel. The gels were administered topically on two test sites on the lower back of the subject, each 1.76 cm2 in size. The two test sites were UVB irradiated on the previous day, between 22 and 26 hours (24 ± 2 hours) before dosing.</description>
          </group>
          <group group_id="O8">
            <title>Cohort 2: Voltarol Oral Tablet</title>
            <description>Cohort 2: Diclofenac, Voltarol oral tablet (50 mg)&#xD;
Diclofenac: Subjects were randomised to receive 22 uL (20 ± l mg) DCF100 Gel (diclofenac 2% w/w) / DCF100 Gel (diclofenac 4% w/w) / Matching Placebo DCF100 Gel / Voltarol® 12 Hour Emulgel® P 2.32% Gel. The gels were administered topically on two test sites on the lower back of the subject, each 1.76 cm2 in size. The two test sites were UVB irradiated on the previous day, between 22 and 26 hours (24 ± 2 hours) before dosing.</description>
          </group>
          <group group_id="O9">
            <title>Cohort 2: DCF100 Placebo Gel</title>
            <description>Cohort 2: DCF100 matching placebo gel&#xD;
Placebo: The placebo gels were administered topically on two test sites on the lower back of the subject, each 1.76 cm2 in size. The two test sites were UVB irradiated on the previous day, between 22 and 26 hours (24 ± 2 hours) before dosing.</description>
          </group>
          <group group_id="O10">
            <title>Cohort 3: SPR300 Gel (15%:7%)</title>
            <description>Cohort 3: Methyl-salicylate / Menthol, SPR300 gel (15%:7%, w/w; ratio of Methylsalicylate / Menthol)&#xD;
Methyl-salicylate / Menthol: Subjects were randomised to receive 22 uL (20 ± l mg) SPR300 Gel / Matching Placebo SPR300 Gel. The gels were administered topically on two test sites on the lower back of the subject, each 1.76cm2 in size. The two test sites were UVB irradiated on the previous day, between 22 and 26 hours (24 ± 2 hours) before dosing.</description>
          </group>
          <group group_id="O11">
            <title>Cohort 3: SPR300 Placebo Gel</title>
            <description>Cohort 3: SPR300 matching placebo gel&#xD;
Placebo: The placebo gels were administered topically on two test sites on the lower back of the subject, each 1.76 cm2 in size. The two test sites were UVB irradiated on the previous day, between 22 and 26 hours (24 ± 2 hours) before dosing.</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Events (AEs)</title>
          <description>Local and systemic Adverse Events (AEs).</description>
          <units>Events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="20"/>
                <count group_id="O5" value="20"/>
                <count group_id="O6" value="20"/>
                <count group_id="O7" value="20"/>
                <count group_id="O8" value="20"/>
                <count group_id="O9" value="20"/>
                <count group_id="O10" value="20"/>
                <count group_id="O11" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="2"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="3"/>
                    <measurement group_id="O11" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Determine Vital Signs and Electrocardiograms (ECGs) That Were Abnormal to Ensure Safety and Well Being of the Subjects</title>
        <description>To determine Vital Signs and Electrocardiograms (ECGs) that were abnormal to ensure safety and well being of the subjects</description>
        <time_frame>Estimated study duration for each subject will be approximately 6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: TIB200 Gel 10%</title>
            <description>Cohort 1: Ibuprofen, TIB200 gel (10%, w/w)&#xD;
Ibuprofen: Single topical dose per 1.76 cm2 test site of: 22 microliters (μL) (20 ± l mg)* of TIB200 Gel (ibuprofen 10% w/w) (Test Gel) or 22 μL (20 ± l mg)* of matching placebo TIB200 Gel (placebo gel) or 22 μL (20 ± l mg)* of Nurofen Maximum Strength Gel (ibuprofen 10% w/w) (reference gel).</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1: Nurofen Gel 10%</title>
            <description>Cohort 1: Ibuprofen, Nurofen Max Strength gel (10%, w/w)&#xD;
Ibuprofen: Single topical dose per 1.76 cm2 test site of: 22 microliters (μL) (20 ± l mg)* of TIB200 Gel (ibuprofen 10% w/w) (Test Gel) or 22 μL (20 ± l mg)* of matching placebo TIB200 Gel (placebo gel) or 22 μL (20 ± l mg)* of Nurofen Maximum Strength Gel (ibuprofen 10% w/w) (reference gel).</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1: Nurofen Tablets</title>
            <description>Cohort 1: Ibuprofen, Nurofen oral tablets (2 x 400 mg)&#xD;
Ibuprofen: Single topical dose per 1.76 cm2 test site of: 22 microliters (μL) (20 ± l mg)* of TIB200 Gel (ibuprofen 10% w/w) (Test Gel) or 22 μL (20 ± l mg)* of matching placebo TIB200 Gel (placebo gel) or 22 μL (20 ± l mg)* of Nurofen Maximum Strength Gel (ibuprofen 10% w/w) (reference gel).</description>
          </group>
          <group group_id="O4">
            <title>Cohort 1: TIB200 Placebo Gel</title>
            <description>Cohort 1: TIB200 matching placebo gel&#xD;
Placebo: The placebo gels were administered topically on two test sites on the lower back of the subject, each 1.76 cm2 in size. The two test sites were UVB irradiated on the previous day, between 22 and 26 hours (24 ± 2 hours) before dosing.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 2: DCF100 Gel 2%</title>
            <description>Cohort 2: Diclofenac, DCF100 gel (2% w/w)&#xD;
Diclofenac: Subjects were randomised to receive 22 uL (20 ± l mg) DCF100 Gel (diclofenac 2% w/w) / DCF100 Gel (diclofenac 4% w/w) / Matching Placebo DCF100 Gel / Voltarol® 12 Hour Emulgel® P 2.32% Gel. The gels were administered topically on two test sites on the lower back of the subject, each 1.76 cm2 in size. The two test sites were UVB irradiated on the previous day, between 22 and 26 hours (24 ± 2 hours) before dosing.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 2: DCF100 Gel 4%</title>
            <description>Cohort 2: Diclofenac, DCF100 gel (4% w/w)&#xD;
Diclofenac: Subjects were randomised to receive 22 uL (20 ± l mg) DCF100 Gel (diclofenac 2% w/w) / DCF100 Gel (diclofenac 4% w/w) / Matching Placebo DCF100 Gel / Voltarol® 12 Hour Emulgel® P 2.32% Gel. The gels were administered topically on two test sites on the lower back of the subject, each 1.76 cm2 in size. The two test sites were UVB irradiated on the previous day, between 22 and 26 hours (24 ± 2 hours) before dosing.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 2: Voltaren Gel 2%</title>
            <description>Cohort 2: Diclofenac, Voltaren Emulgel (2%)&#xD;
Diclofenac: Subjects were randomised to receive 22 uL (20 ± l mg) DCF100 Gel (diclofenac 2% w/w) / DCF100 Gel (diclofenac 4% w/w) / Matching Placebo DCF100 Gel / Voltarol® 12 Hour Emulgel® P 2.32% Gel. The gels were administered topically on two test sites on the lower back of the subject, each 1.76 cm2 in size. The two test sites were UVB irradiated on the previous day, between 22 and 26 hours (24 ± 2 hours) before dosing.</description>
          </group>
          <group group_id="O8">
            <title>Cohort 2: Voltarol Oral Tablet</title>
            <description>Cohort 2: Diclofenac, Voltarol oral tablet (50 mg)&#xD;
Diclofenac: Subjects were randomised to receive 22 uL (20 ± l mg) DCF100 Gel (diclofenac 2% w/w) / DCF100 Gel (diclofenac 4% w/w) / Matching Placebo DCF100 Gel / Voltarol® 12 Hour Emulgel® P 2.32% Gel. The gels were administered topically on two test sites on the lower back of the subject, each 1.76 cm2 in size. The two test sites were UVB irradiated on the previous day, between 22 and 26 hours (24 ± 2 hours) before dosing.</description>
          </group>
          <group group_id="O9">
            <title>Cohort 2: DCF100 Placebo Gel</title>
            <description>Cohort 2: DCF100 matching placebo gel&#xD;
Placebo: The placebo gels were administered topically on two test sites on the lower back of the subject, each 1.76 cm2 in size. The two test sites were UVB irradiated on the previous day, between 22 and 26 hours (24 ± 2 hours) before dosing.</description>
          </group>
          <group group_id="O10">
            <title>Cohort 3: SPR300 Gel (15%:7%)</title>
            <description>Cohort 3: Methyl-salicylate / Menthol, SPR300 gel (15%:7%, w/w; ratio of Methylsalicylate / Menthol)&#xD;
Methyl-salicylate / Menthol: Subjects were randomised to receive 22 uL (20 ± l mg) SPR300 Gel / Matching Placebo SPR300 Gel. The gels were administered topically on two test sites on the lower back of the subject, each 1.76cm2 in size. The two test sites were UVB irradiated on the previous day, between 22 and 26 hours (24 ± 2 hours) before dosing.</description>
          </group>
          <group group_id="O11">
            <title>Cohort 3: SPR300 Placebo Gel</title>
            <description>Cohort 3: SPR300 matching placebo gel&#xD;
Placebo: The placebo gels were administered topically on two test sites on the lower back of the subject, each 1.76 cm2 in size. The two test sites were UVB irradiated on the previous day, between 22 and 26 hours (24 ± 2 hours) before dosing.</description>
          </group>
        </group_list>
        <measure>
          <title>To Determine Vital Signs and Electrocardiograms (ECGs) That Were Abnormal to Ensure Safety and Well Being of the Subjects</title>
          <description>To determine Vital Signs and Electrocardiograms (ECGs) that were abnormal to ensure safety and well being of the subjects</description>
          <units>Abnormal readings</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="20"/>
                <count group_id="O5" value="20"/>
                <count group_id="O6" value="20"/>
                <count group_id="O7" value="20"/>
                <count group_id="O8" value="20"/>
                <count group_id="O9" value="20"/>
                <count group_id="O10" value="20"/>
                <count group_id="O11" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 months</time_frame>
      <desc>All AE's were reported as this was a phase 1 study&#xD;
The threshold for reporting was therefore greater than 0%</desc>
      <group_list>
        <group group_id="E1">
          <title>Cohort 1: TIB200 Gel 10%</title>
          <description>Cohort 1: Ibuprofen, TIB200 gel (10%, w/w)&#xD;
Ibuprofen: Single topical dose per 1.76 cm2 test site of: 22 microliters (μL) (20 ± l mg)* of TIB200 Gel (ibuprofen 10% w/w) (Test Gel) or 22 μL (20 ± l mg)* of matching placebo TIB200 Gel (placebo gel) or 22 μL (20 ± l mg)* of Nurofen Maximum Strength Gel (ibuprofen 10% w/w) (reference gel).</description>
        </group>
        <group group_id="E2">
          <title>Cohort 1: Nurofen Gel 10%</title>
          <description>Cohort 1: Ibuprofen, Nurofen Max Strength gel (10%, w/w)&#xD;
Ibuprofen: Single topical dose per 1.76 cm2 test site of: 22 microliters (μL) (20 ± l mg)* of TIB200 Gel (ibuprofen 10% w/w) (Test Gel) or 22 μL (20 ± l mg)* of matching placebo TIB200 Gel (placebo gel) or 22 μL (20 ± l mg)* of Nurofen Maximum Strength Gel (ibuprofen 10% w/w) (reference gel).</description>
        </group>
        <group group_id="E3">
          <title>Cohort 1: Nurofen Tablets</title>
          <description>Cohort 1: Ibuprofen, Nurofen oral tablets (2 x 400 mg)&#xD;
Ibuprofen: Single topical dose per 1.76 cm2 test site of: 22 microliters (μL) (20 ± l mg)* of TIB200 Gel (ibuprofen 10% w/w) (Test Gel) or 22 μL (20 ± l mg)* of matching placebo TIB200 Gel (placebo gel) or 22 μL (20 ± l mg)* of Nurofen Maximum Strength Gel (ibuprofen 10% w/w) (reference gel).</description>
        </group>
        <group group_id="E4">
          <title>Cohort 1: TIB200 Placebo Gel</title>
          <description>Cohort 1: TIB200 matching placebo gel&#xD;
Placebo: The placebo gels were administered topically on two test sites on the lower back of the subject, each 1.76 cm2 in size. The two test sites were UVB irradiated on the previous day, between 22 and 26 hours (24 ± 2 hours) before dosing.</description>
        </group>
        <group group_id="E5">
          <title>Cohort 2: DCF100 Gel 2%</title>
          <description>Cohort 2: Diclofenac, DCF100 gel (2% w/w)&#xD;
Diclofenac: Subjects were randomised to receive 22 uL (20 ± l mg) DCF100 Gel (diclofenac 2% w/w) / DCF100 Gel (diclofenac 4% w/w) / Matching Placebo DCF100 Gel / Voltarol® 12 Hour Emulgel® P 2.32% Gel. The gels were administered topically on two test sites on the lower back of the subject, each 1.76 cm2 in size. The two test sites were UVB irradiated on the previous day, between 22 and 26 hours (24 ± 2 hours) before dosing.</description>
        </group>
        <group group_id="E6">
          <title>Cohort 2: DCF100 Gel 4%</title>
          <description>Cohort 2: Diclofenac, DCF100 gel (4% w/w)&#xD;
Diclofenac: Subjects were randomised to receive 22 uL (20 ± l mg) DCF100 Gel (diclofenac 2% w/w) / DCF100 Gel (diclofenac 4% w/w) / Matching Placebo DCF100 Gel / Voltarol® 12 Hour Emulgel® P 2.32% Gel. The gels were administered topically on two test sites on the lower back of the subject, each 1.76 cm2 in size. The two test sites were UVB irradiated on the previous day, between 22 and 26 hours (24 ± 2 hours) before dosing.</description>
        </group>
        <group group_id="E7">
          <title>Cohort 2: Voltaren Gel 2%</title>
          <description>Cohort 2: Diclofenac, Voltaren Emulgel (2%)&#xD;
Diclofenac: Subjects were randomised to receive 22 uL (20 ± l mg) DCF100 Gel (diclofenac 2% w/w) / DCF100 Gel (diclofenac 4% w/w) / Matching Placebo DCF100 Gel / Voltarol® 12 Hour Emulgel® P 2.32% Gel. The gels were administered topically on two test sites on the lower back of the subject, each 1.76 cm2 in size. The two test sites were UVB irradiated on the previous day, between 22 and 26 hours (24 ± 2 hours) before dosing.</description>
        </group>
        <group group_id="E8">
          <title>Cohort 2: Voltarol Oral Tablet</title>
          <description>Cohort 2: Diclofenac, Voltarol oral tablet (50 mg)&#xD;
Diclofenac: Subjects were randomised to receive 22 uL (20 ± l mg) DCF100 Gel (diclofenac 2% w/w) / DCF100 Gel (diclofenac 4% w/w) / Matching Placebo DCF100 Gel / Voltarol® 12 Hour Emulgel® P 2.32% Gel. The gels were administered topically on two test sites on the lower back of the subject, each 1.76 cm2 in size. The two test sites were UVB irradiated on the previous day, between 22 and 26 hours (24 ± 2 hours) before dosing.</description>
        </group>
        <group group_id="E9">
          <title>Cohort 2: DCF100 Placebo Gel</title>
          <description>Cohort 2: DCF100 matching placebo gel&#xD;
Placebo: The placebo gels were administered topically on two test sites on the lower back of the subject, each 1.76 cm2 in size. The two test sites were UVB irradiated on the previous day, between 22 and 26 hours (24 ± 2 hours) before dosing.</description>
        </group>
        <group group_id="E10">
          <title>Cohort 3: SPR300 Gel (15%:7%)</title>
          <description>Cohort 3: Methyl-salicylate / Menthol, SPR300 gel (15%:7%, w/w; ratio of Methylsalicylate / Menthol)&#xD;
Methyl-salicylate / Menthol: Subjects were randomised to receive 22 uL (20 ± l mg) SPR300 Gel / Matching Placebo SPR300 Gel. The gels were administered topically on two test sites on the lower back of the subject, each 1.76cm2 in size. The two test sites were UVB irradiated on the previous day, between 22 and 26 hours (24 ± 2 hours) before dosing.</description>
        </group>
        <group group_id="E11">
          <title>Cohort 3: SPR300 Placebo Gel</title>
          <description>Cohort 3: SPR300 matching placebo gel&#xD;
Placebo: The placebo gels were administered topically on two test sites on the lower back of the subject, each 1.76 cm2 in size. The two test sites were UVB irradiated on the previous day, between 22 and 26 hours (24 ± 2 hours) before dosing.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (17.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>toothache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Soft Stools</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain Burning</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Commom Cold</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Frequency of Micturation Increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Runny Nose</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Itching</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Erythematous Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot Flush</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Director of Clinical Development</name_or_title>
      <organization>Futura Medical Developments Limited</organization>
      <phone>01483685683</phone>
      <email>tim.holland@futuramedical.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

